Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Møller, Daniel V ^a   Pecini, Redi ^a   Gustafsson, Finn ^a   Hassager, Christian ^a   Hedley, Paula ^b   Jespersgaard, Cathrine ^b   Torp Pedersen, Christian ^c   Christiansen, Michael ^b   Køber, Lars V ^a  

^a Rigshospitalet   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOCHROMATOSIS PROTEIN; HEMOGLOBIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEMOCHROMATOSIS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE; ADULT; AGED; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 77955480546     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-117     Document Type: Article

References (31)

1. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358:221-230. 10.1056/NEJMoa073286, 18199861.
2. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008, 15:169-175. 10.1097/MOH.0b013e3282f73335, 18391780.
3. Nagayoshi Y, Nakayama M, Suzuki S, Hokamaki J, Shimomura H, Tsujita K, Fukuda M, Yamashita T, Nakamura Y, Sugiyama S, et al. A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail 2008, 10:1001-1006. 10.1016/j.ejheart.2008.07.012, 18725184.
4. Piperno A, Roetto A, Mariani R, Pelucchi S, Corengia C, Daraio F, Piga A, Garozzo G, Camaschella C. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004, 89:359-360.
5. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33:21-22. 10.1038/ng1053, 12469120.
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408. 10.1038/ng0896-399, 8696333.
7. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Kosty M, Venditti CP, Phatak PD, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996, 22:187-194. 10.1006/bcmd.1996.0027, 8931958.
8. Wiggers P, Dalhoj J, Kiaer H, Ring-Larsen H, Petersen PH, Blaabjerg O, Horder M. Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991, 230:265-270. 10.1111/j.1365-2796.1991.tb00441.x, 1895049.
9. Milman N, Koefoed P, Pedersen P, Nielsen FC, Eiberg H. Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. Eur J Haematol 2003, 71:403-407. 10.1046/j.0902-4441.2003.00156.x, 14703688.
10. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008, 88:7-15. 10.1007/s12185-008-0120-5, 2516548, 18594779.
11. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001, 154:739-746. 10.1016/S0021-9150(00)00623-7, 11257277.
12. van der AD, Rovers MM, Grobbee DE, Marx JJ, Waalen J, Ellervik C, Nordestgaard BG, Olynyk JK, Mills PR, Shepherd J, et al. Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjects. Circ Cardiovasc Genet 2008, 1:43-50. 10.1161/CIRCGENETICS.108.773176, 20031541.
13. Hannuksela J, Leppilampi M, Peuhkurinen K, Karkkainen S, Saastamoinen E, Helio T, Kaartinen M, Nieminen MS, Nieminen P, Parkkila S. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005, 7:103-108. 10.1016/j.ejheart.2004.03.007, 15642540.
14. Mahon NG, Coonar AS, Jeffery S, Coccolo F, Akiyu J, Zal B, Houlston R, Levin GE, Baboonian C, McKenna WJ. Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy. Heart 2000, 84:541-547. 10.1136/heart.84.5.541, 1729493, 11040018.
15. Pereira AC, Cuoco MA, Mota GF, da Silva FF, Freitas HF, Bocchi EA, Soler JM, Mansur AJ, Krieger JE. Hemochromatosis gene variants in patients with cardiomyopathy. Am J Cardiol 2001, 88:388-391. 10.1016/S0002-9149(01)01684-8, 11545759.
16. Torp-Pedersen C, Kober L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, Dickstein K, Haghfelt T, Ohlin H, McMurray JJ. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 2008, 10:89-95. 10.1016/j.ejheart.2007.10.012, 18164245.
17. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J 1994, 15:1616-1620.
18. Pecini R, Moller DV, Torp-Pedersen C, Hassager C, Kober L. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol 2010,
19. Pedersen P, Melsen GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol 2008, 87:735-740. 10.1007/s00277-008-0506-8, 18542962.
20. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006, 281:28494-28498. 10.1074/jbc.C600197200, 16893896.
21. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999, 93:2502-2505.
22. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007, 46:1071-1080. 10.1002/hep.21885, 17828789.
23. Ellervik C, Tybjaerg-Hansen A, Appleyard M, Sillesen H, Boysen G, Nordestgaard BG. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology 2007, 68:1025-1031. 10.1212/01.wnl.0000257814.77115.d6, 17389307.
24. Demant AW, Schmiedel A, Buttner R, Lewalter T, Reichel C. Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy. Clin Res Cardiol 2007, 96:900-903. 10.1007/s00392-007-0568-y, 17694379.
25. Phatak PD, Ryan DH, Cappuccio J, Oakes D, Braggins C, Provenzano K, Eberly S, Sham RL. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002, 29:41-47. 10.1006/bcmd.2002.0536, 12482402.
26. Van VH, Langlois M, Delanghe J, Horsmans Y, Michielsen P, Henrion J, Cartuyvels R, Billiet J, De VM, Leroux-Roels G. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001, 35:707-711. 10.1016/S0168-8278(01)00203-3, 11738096.
27. Carter K, Bowen DJ, McCune CA, Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol 2003, 122:326-332. 10.1046/j.1365-2141.2003.04436.x, 12846904.
28. Coppin H, Darnaud V, Kautz L, Meynard D, Aubry M, Mosser J, Martinez M, Roth MP. Gene expression profiling of Hfe-/- liver and duodenum in mouse strains with differing susceptibilities to iron loading: identification of transcriptional regulatory targets of Hfe and potential hemochromatosis modifiers. Genome Biol 2007, 8:R221. 10.1186/gb-2007-8-10-r221, 2246295, 17945001.
29. Dunn T, Blankenship D, Beal N, Allen R, Schechter E, Moore W, Perveen G, Eichner J. HFE mutations in heart disease. Heart Vessels 2008, 23:348-355. 10.1007/s00380-008-1047-8, 18810584.
30. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350. 10.1001/jama.292.3.344, 15265849.
31. Groenveld HF, Januzzi JL, Damman K, van WJ, Hillege HL, van Veldhuisen DJ, van der MP. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818-827. 10.1016/j.jacc.2008.04.061, 18755344.